Breaking Finance News

Horizon Pharma (NASDAQ:HZNP) has been downgraded from Outperform to Market Perform in a report by Cowen & Co. today.

Cowen & Co. has downgraded Horizon Pharma(NASDAQ:HZNP) from Outperform to Market Perform in a report released on 9/16/2016.

On 9/13/2016, Mizuho Securities reported on Horizon Pharma(NASDAQ:HZNP) bumped the target price from $30.00 to $33.00. At the time, this suggested an upside of 0.75%.

Displaying a price of $19.10, Horizon Pharma (NASDAQ:HZNP) traded 0.79% lower on the day. The last stock price is up 10.81% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. Horizon Pharma has been tracking to a 50-day moving average of $20.23 and two hundred day average of $17.53. 1,298,780 shares of Horizon Pharma traded hands, down from ann average trading volume of 4,266,340

Recent Performance Chart:

Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma has a one-year low of $12.86 and a one-year high of $32.34 and has a total market value of $0.0.

Also covering Horizon Pharma’s price target, a total of 13 analysts have reported on the company. The average target price is $30.23 with four firms rating the company a strong buy, six firms rating the stock a buy, one firm rating the stock a hold, one analyst rating the company to underperform, and lastly 0 analystsrating the company as sell.

General Company Details For Horizon Pharma (NASDAQ:HZNP)

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units. Its segment focuses on the identification, development, acquisition and commercialization of differentiated and accessible medicines. Its marketed medicines include ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate and caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% w/w, or PENNSAID 2%, RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). It also developed DUEXIS and RAYOS, and known as LODOTRA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *